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Angiotensin II directly induces muscle protein catabolism through
the ubiquitin–proteasome proteolytic pathway and may play a
role in cancer cachexia
PM Sanders1, ST Russell1 and MJ Tisdale*,1
1Pharmaceutical Sciences Research Institute, Aston University, Birmingham B4 7ET, UK
The ability of angiotensin I (Ang I) and II (Ang II) to induce directly protein degradation in skeletal muscle has been studied in murine
myotubes. Angiotensin I stimulated protein degradation with a parabolic dose–response curve and with a maximal effect between
0.05 and 0.1 mM. The effect was attenuated by coincubation with the angiotensin-converting enzyme (ACE) inhibitor imidaprilat,
suggesting that angiotensin I stimulated protein degradation through conversion to Ang II. Angiotensin II also stimulated protein
breakdown with a similar dose–response curve, and with a maximal effect between 1 and 2.5mM. Total protein degradation, induced
by both Ang I and Ang II, was attenuated by the proteasome inhibitors lactacystin (5 mM) and MG132 (10 mM), suggesting that the
effect was mediated through upregulation of the ubiquitin–proteasome proteolytic pathway. Both Ang I and Ang II stimulated an
increased proteasome ‘chymotrypsin-like’ enzyme activity as well as an increase in protein expression of 20S proteasome a-subunits,
the 19S subunits MSS1 and p42, at the same concentrations as those inducing protein degradation. The effect of Ang I was
attenuated by imidaprilat, confirming that it arose from conversion to Ang II. These results suggest that Ang II stimulates protein
degradation in myotubes through induction of the ubiquitin–proteasome pathway. Protein degradation induced by Ang II was
inhibited by insulin-like growth factor and by the polyunsaturated fatty acid, eicosapentaenoic acid. These results suggest that Ang II
has the potential to cause muscle atrophy through an increase in protein degradation. The highly lipophilic ACE inhibitor imidapril
(Vitort) (30 mg kg1) attenuated the development of weight loss in mice bearing the MAC16 tumour, suggesting that Ang II may
play a role in the development of cachexia in this model.
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Cachexia is a progressive wasting syndrome, responsible for the
death of about 20% of cancer patients (Inagaki et al, 1974), which
involves substantial loss of both adipose tissue and skeletal muscle
protein. Cachexia is common in many chronic or end-stage
diseases such as infections, AIDS, congestive heart failure (CHF)
and tuberculosis, as well as cancer. In all cases, loss of fat-free mass
involves only skeletal muscle and not visceral tissues, and is
reflected in an increased morbidity and mortality. In cancer
cachexia, the mechanism for the selective depletion of skeletal
muscle is thought to involve tumour factors, such as proteolysis-
inducing factor (PIF), which inhibits protein synthesis and
increases protein degradation in skeletal muscle, without affecting
visceral protein reserves (Lorite et al, 1997). Studies in other
wasting conditions suggest that other factors may be involved.
Cytokines have also been shown to play an important role in
muscle wasting (Zoico and Roubenoff, 2002). Thus, treatment of
patients with CHF with the angiotensin-converting enzyme (ACE)
inhibitor enalapril, in combination with digoxin and a diuretic,
produced both increased subcutaneous (s.c.) fat and greater
muscle bulk, together with a significant elevation in plasma
albumin (Adigun and Ajayi, 2001). Angiotensin-converting en-
zyme inhibitor treatment has also been shown to halt or slow the
decline in muscle strength in elderly women with hypertension and
without CHF (Onder et al, 2002). Angiotensin-converting enzyme
degrades vasodilator kinases and generates vasoconstrictor
angiotensin II (Ang II). Angiotensin II has physiological effects
and is capable of causing anorexia and wasting in animal models.
Thus, infusion of Ang II into the rat produced a loss of between 18
and 26% of body weight by 1 week (Brink et al, 1996). Although
74% of this loss was attributable to a reduction in food intake,
there were significant differences in body weight and lean muscle
mass between Ang II-infused and pair-fed control rats. In skeletal
muscle, Ang II did not significantly decrease protein synthesis, but
accelerated overall protein breakdown, possibly through the
ubiquitin–proteasome pathway (Brink et al, 2001). Further studies
in rats showed that mRNA levels of the ubiquitin ligases atrogin-1
and muscle ring-finger-1 (MURF1) were upregulated in skeletal
muscle by Ang II, suggesting that protein degradation was
mediated through the ubiquitin–proteasome proteolytic pathway
(Song et al, 2005). This raises the possibility that Ang II directly
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enhances expression and activity of this pathway, as does the
tumour factor PIF (Lorite et al, 2001). However, the effect in vivo
was considered to be indirect and mediated by intermediate factors
such as glucocorticoids (Song et al, 2005). To determine whether
Ang II directly accelerates protein degradation, the current study
has been conducted in murine myotubes in vitro. To determine
whether Ang II plays a role in cancer cachexia, the effect of the
ACE inhibitor imidapril (Vitort) has been evaluated on the
induction of weight loss in mice induced by the MAC16 tumour.
MATERIALS AND METHODS
Materials
L-[2, 6-3H] Phenylalanine (sp. act. 48 Ci mmol1), hybond A
nitrocellulose membranes and enhanced chemiluminescence
(ECL) development kits were from Amersham International
(Bucks, UK). Foetal calf serum (FCS), horse serum (HS) and
Dulbecco’s modified Eagle’s medium (DMEM) were purchased
from Invitrogen (Paisley, Scotland). Mouse monoclonal antibodies
to 20S proteasome a-subunits, MSS1 and p42 were from Affiniti
Research Products (Exeter, UK). Mouse monoclonal antibody to
myosin heavy chain was from Novocastra (Newcastle, UK). Rabbit
polyclonal antisera to mouse b-actin and Ang I and Ang II were
from Sigma Aldridge (Dorset, UK). Peroxidase-conjugated rabbit
anti-mouse antibody and peroxidase-conjugated goat anti-rabbit
antibody were purchased from Dako Ltd (Cambridge, UK). Both
imidapril hydrochloride (Vitort) and imidaprilat were kindly
supplied by Ark Therapeutics Ltd (London, UK). Angiotensin I
and Ang II receptor inhibitors were purchased from Tocris
(Avonmouth, UK).
Animals
Pure strain male NMRI mice (average weight 25 g) were obtained
from our own inbred colony and transplanted with fragments of the
MAC16 tumour s.c. into the flank by means of a trochar, selecting
from donor animals with established weight loss, as described
previously (Beck and Tisdale, 1987). Transplanted animals were fed
a rat and mouse breeding diet (Special Diet Services, Witham, UK)
and water ad libitum and weight loss was evident 10–12 days after
tumour implantation without a reduction in food intake (Beck and
Tisdale, 1987). When weight loss became apparent (5–7%), animals
were randomised to receive imidapril hydrochloride (either 1 or
10 mg kg1 dissolved in water) p.o. daily 3 or water control. Both
tumour volume and body weight were monitored daily and animals
were terminated by cervical dislocation when the body weight loss
reached 25%. All animal experiments followed a strict protocol,
agreed with the British Home Office and the ethical guidelines that
were followed meet the standards required by the UKCCR (Work-
man et al, 1998). The dimensions of the tumour were measured by
callipers and tumour volume calculated from the following formula:
volume¼ (lengthwidth)/2.
Cell culture
Murine C2C12 myoblasts were grown in DMEM supplemented with
10% FCS, glutamine and 1% penicillin–streptomycin under an
atmosphere of 10% CO2 in air at 371C. When the cells reached
confluence, they were allowed to fuse to form myotubes in DMEM
containing 2% HS, with medium changes every 2 days. Differ-
entiation was complete within 5–7 days and myotubes were used
experimentally no later than 4 days postdifferentiation.
Measurement of protein degradation
In vitro Myotubes were prelabelled for 24 h with L-[2, 6-3H]
phenylalanine (10 mCi; sp. act. 1.32 Ci mmol1) and were washed
extensively prior to experimentation, as described previously
(Whitehouse and Tisdale, 2003). Protein degradation was deter-
mined by the release of [2, 6-3H] phenylalanine into the medium
after 24 h incubation with various concentrations of Ang I or Ang
II in the absence or presence of inhibitors added 2 h prior to
angiotensin. Cold phenylalanine (2 mM) was added to prevent
reincorporation of radioactivity into the cells.
Ex vivo Murine soleus muscles were preincubated for 45 min in
3 ml oxygenated (95% oxygen/5% carbon dioxide) Krebs –Hense-
leit bicarbonate buffer, pH 7.4, containing 5 mmol l1 glucose and
0.5 mmol l1 cycloheximide. Protein degradation was determined
in the absence and presence of Ang II, with or without receptor
antagonists by the release of tyrosine over a 2 h period (Waalkes
and Udenfriend, 1957).
Measurement of proteasome activity
‘Chymotrypsin-like’ enzyme activity was determined fluorimetri-
cally by the method of Orino et al (1991), by the release of
aminomethyl coumarin (AMC) from the fluorogenic peptide
succinyl-LLVY-AMC. This method has been described previously
for C2C12 myotubes (Whitehouse and Tisdale, 2003). Activity was
measured in the absence and presence of the specific proteasome
inhibitor lactacystin (10 mM). Only lactacystin-suppressible activity
was considered to be proteasome specific.
Western blot analysis
Myotubes were incubated with various concentrations of Ang II as
depicted in the figure legends, after which the medium was
removed and the cells were washed with PBS and scraped from the
plastic surface. They were then sonicated at 41C in 500–2000 ml of
20 mM Tris-HCl, pH 7.5, 2 mM ATP, 5 mM MgCl2 and 1 mM
dithiothreitol. Samples of cytosolic protein (5mg), formed by
centrifugation at 18 000 g for 5 min, were resolved on 12% sodium
dodecylsulfate– polyacrylamide gels and transferred to 0.45 mm
nitrocellulose membranes, which had been blocked with 5%
Marvel in Tris-buffered saline, pH 7.5, at 41C overnight. The
primary antibodies were used at a dilution of 1 : 1000, except for
actin (1 : 200) and myosin (1 : 250), and the secondary antibodies
were also used at a dilution of 1 : 2000. Incubation was for 1 h at
room temperature and development was by ECL (Amersham, UK).
Blots were scanned by a densitometer to quantitate differences.
Statistical analysis
Differences in means between groups was determined by one-way
ANOVA, followed by Tukey’s post-test.
RESULTS
To determine a direct effect on protein degradation, Ang I was
added to murine myotubes, which had been previously labelled
with [3H] phenylalanine, and the release of radiolabel after 24 h
incubation provided a monitor of total protein degradation. The
results presented in Figure 1A show that Ang I significantly
stimulated protein degradation, with a parabolic dose–response
curve, as previously observed with PIF (Whitehouse and Tisdale,
2003), and with a maximal effect at concentrations between 0.05
and 0.1 mM. The effect was attenuated by coincubation with
imidaprilat (50 mM), the active metabolite of the highly lipophilic
ACE inhibitor imidapril (Vitort) (Mabuchi et al, 1999). These
results suggest that Ang I stimulates protein degradation in muscle
through the conversion to Ang II. This was confirmed by the
results shown in Figure 1B where Ang II also stimulated total
protein degradation in myotubes, with a parabolic dose–response
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curve, and with a maximal effect at a concentration of 1 –2.5 mM.
Both Ang I and Ang II increased total protein degradation by 30%,
which is similar to that induced by glucocorticoids (Sacheck et al,
2004) and PIF (Smith et al, 1999). Protein degradation in myotubes
initiated by both Ang I (Figure 1C) and Ang II (Figure 1D) was
attenuated by the proteasome inhibitors lactacystin (5mM) and
MG132 (10 mM), suggesting that upregulation of the ubiquitin–
proteasome proteolytic pathway was responsible for the increased
protein breakdown.
To confirm this, the effect on proteasome functional activity was
measured as the ‘chymotrypsin-like’ enzyme activity, the pre-
dominant proteasome proteolytic activity. Both Ang I (Figure 2A)
and Ang II (Figure 2B) increased the proteasome ‘chymotrypsin-
like’ enzyme activity with a dose–response curve similar to that
for total protein degradation (Figure 1). As with total protein
degradation, the effect of Ang I was attenuated by imidaprilat
(Figure 2A). Western blotting showed that Ang I also induced an
increase in protein expression of 20S proteasome a-subunits
(Figure 3A), and p42, an ATPase subunit of the 19S regulator
(Figure 3B), while decreasing the expression of myosin
(Figure 3D). Angiotensin II also induced an increase in protein
expression of p42 (Figure 4A), MSS1, another ATPase subunit of
the 19S regulator (Figure 4B), and the decreased expression of
myosin (Figure 4C) at the same concentrations as those inducing
protein degradation, suggesting that protein breakdown was due to
the induction of the ubiquitin– proteasome pathway. The effect of
Ang I was attenuated by 50 mM imidaprilat, confirming that it arose
from the formation of Ang II (Figure 3).
Since the increased protein degradation produced by Ang II has
been suggested to be due to an inhibitory effect on the autocrine
insulin-like growth factor (IGF-I) system (Brink et al, 2001), the
effect of IGF-I on total protein degradation induced by Ang II
(1mM) was determined in murine myotubes. Insulin-like growth
factor-I completely attenuated the increase in protein degradation
induced by Ang II at concentrations between 25 and 100 ng ml1
(Figure 5A), and this was accompanied by complete suppression of
the increase in ‘chymotrypsin-like’ enzyme activity (Figure 5B) and
increase in the expression of 20S proteasome a-subunits
(Figure 5C). These results suggest that IGF-I attenuates protein
degradation induced by Ang II in skeletal muscle through
downregulation of the increase in the expression of the
ubiquitin–proteasome proteolytic pathway.
In order to determine whether the mechanism of activation of
protein degradation by Ang II was similar to that of PIF, protein
degradation was measured in myotubes coincubated with eicosa-
pentaenoic acid (EPA), which interrupts cellular signalling leading
to an increase in proteasome expression (Smith et al, 1999).
Stimulation of total protein degradation by both Ang I (Figure 1A)
and Ang II (Figure 1B) was completely attenuated by EPA (50 mM),
as was also the increase in chymotrypsin-like enzyme activity
(Figure 2B), and the expression of 20S proteasome a-subunits
(Figure 6A), MSS1 (Figure 6B) and p42 (Figure 6C) as determined
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Figure 1 (A) Effect of Ang I on total protein degradation in murine myotubes in the absence (E) or presence of imidaprilat (50 mM) (m) or EPA (50 mM)
(&). (B) Effect of Ang II on total protein degradation in murine myotubes after 24 h incubation in the absence (E) or presence (&) of 50mM EPA. (C)
Effect of Ang I and (D) effect of Ang II on total protein degradation in the absence (E) or presence of lactacystin (5 mM) (m) or MG132 (10 mM) (&).
Differences from control in the presence of Ang I and Ang II are indicated as c, Po0.001, while differences in the presence of the inhibitors are indicated as e,
Po0.01 or f, Po0.001. n¼ 6.
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by Western blotting. These results suggest that the mechanism
of induction of proteasome expression by Ang II is similar to
that of PIF.
To confirm that the myotubes model was representative of
skeletal muscle, the effect of Ang II on total protein degradation
was determined in mouse soleus muscle ex vivo (Figure 7A). As in
murine myotubes, Ang II directly induced protein degradation in
soleus muscle, as determined by tyrosine release, and was more
effective at lower concentrations than in murine myotubes. To
confirm that the effect was direct and to determine the receptor
involved, the protein degradation assay was performed in the
presence of ZD7155, a selective competitive antagonist for the Ang
II type 1 (AT1) receptor (Junggren et al, 1996) or PD123319, a
selective AT2 receptor antagonist (Blankley et al, 1991), or
saralasin, a competitive nonselective Ang II antagonist (Steinhau-
sen et al, 1986). The results in Figure 7A show attenuation of the
increased protein degradation by both PD123319 and saralasin,
while ZD7155 had no effect. This suggests that Ang II induces
protein degradation in skeletal muscle through interaction with the
AT2 receptor. To confirm that the murine myotubes system was
representative of skeletal muscle, the effect of the receptor
antagonists on Ang II-induced protein degradation was deter-
mined in myotubes (Figure 7B). The effect was similar to that
observed in soleus muscle with both PD123319 and saralasin
attenuating the effect, while ZD7155 was unaffected. Thus, both in
myotubes and skeletal muscle, Ang II induces protein degradation
through the AT2 receptor, supporting the hypothesis that the effect
of Ang II is a direct effect on skeletal muscle.
To evaluate the role of Ang II in cancer cachexia, mice bearing
the cachexia-inducing MAC16 colon adenocarcinoma cachexia
model were treated daily with the highly lipophilic ACE inhibitor
imidapril. The reason for the choice of this particular inhibitor is
that it is currently undergoing clinical evaluation for the treatment
of cachexia in cancer patients. At a dose level of 30 mg kg1,
imidapril attenuated the development of weight loss (Figure 8A)
and stabilised the increase in tumour volume (Figure 8B). The
effect was dose related and was not seen with lower dose levels
(3 mg kg1). These results suggest that Ang II plays a role in the
development of cachexia in the MAC16 model.
DISCUSSION
This study has shown that Ang II is directly catabolic to skeletal
muscle increasing intracellular protein degradation through an
increased expression of the ubiquitin–proteasome proteolytic
pathway. Ang I also mediates the same effects through conversion
to Ang II by ACE, since the ACE inhibitor imidaprilat, the active
metabolite of imidapril, in which an ethyl ester group is
hydrolysed (Mabuchi et al, 1999), attenuates the action of Ang I.
There is also evidence to suggest that formation of Ang II may
contribute to the loss of body tissue in mice bearing the MAC16
tumour, since imidapril attenuated the development of weight loss
in this model. Ang II directly stimulates tumour necrosis factor-a
(TNF-a) and interleukin-6 (IL-6) production in human peripheral
monocytes and ACE inhibitors inhibit LPS-induced TNF-a
production (Peeters et al, 1998). However, the activity of imidapril
in the MAC16 model could not be explained by an effect on TNF-a
or IL-6 production, since we have previously shown no involve-
ment of these cytokines in the cachectic process in this model
(Mulligan et al, 1992).
Instead, Ang II directly stimulates protein degradation in
myotube cultures through an increased expression and activity
of key components of the ubiquitin– proteasome proteolytic
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Figure 2 Effect of Ang I (A) and Ang II (B) on the ‘chymotrypsin-like’ enzyme activity of the proteasome in the absence (’) or presence of imidaprilat
(50 mM) (&) or EPA (50 mM) ( ). Differences from control in the presence of Ang I or Ang II are indicated as b, Po0.01 or c, Po0.001, while differences in
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pathway. The increased expression of 20S a-subunits would
suggest a higher number of proteasomes, while the increased
expression of the ATPases MSS1 and p42 provides energy for the
breakdown of ubiquitinated proteins by the 26S proteasome
through the hydrolysis of ATP (Coux et al, 1996), as well as for the
assembly of the 26S proteasome through the ATP-dependent
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association of the 20S proteasome with the 19S regulator
(Tanahashi et al, 1999). The decreased level of myosin in myotubes
treated with Ang I/Ang II would suggest that a major component of
the total protein degradation came from myofibrillar proteins. The
angiotensin system initiates selective loss of myosin, while actin
levels remain unchanged. A recent report (Acharyya et al, 2004)
has shown TNF-a plus interferon g to induce selective loss of
myosin in murine myotubes, and this was also found in tibialis
anterior muscle from the hind limb of cachectic mice bearing the
colon 26 tumours. In both cases, actin levels remained constant.
The selective loss of myosin was attributed to transcriptional
repression with the cytokines, or, in the case of mice bearing colon
26 tumours, to selective degradation by the ubiquitin–proteasome
pathway.
This is the first report on the ability of Ang I/Ang II to induce
directly protein catabolism in isolated myotubes, although
previous results (Brink et al, 2001; Song et al, 2005) from in vivo
studies in rats suggested that Ang II induced protein degradation,
but this was suggested to be due to an indirect effect. The
concentration of Ang II inducing protein degradation in vitro is
similar to that which might be achieved by direct infusion into rats
(Brink et al, 2001). This is in the micromolar range, although
normal blood levels of Ang II are below 40 pM. However, this can
increase 4–5-fold in cachectic states (Coates et al, unpublished
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Figure 6 Western blot for the effect of Ang II on the expression of 20S proteasome a-subunits (A) and MSS1 (B) in the absence or presence of 50mM
EPA. The densitometric analysis is the average of three separate blots. An actin loading control is shown in (C). Differences from control are indicated as c,
Po0.001, while differences in the presence of EPA are indicated as d, Po0.05 or f, Po0.001.
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results) and the tissue concentrations are likely to be much higher,
although they have not been measured in cachectic patients. The
observation in the current study that protein degradation induced
by Ang II in both soleus muscle and murine myotubes can be
blocked by AT2 receptor antagonists, but not AT1, suggests that
this is a physiologically relevant process.
The increase in protein degradation and ubiquitin ligases
induced by Ang II in vivo were shown to be blocked by muscle-
specific expression of IGF-I, suggesting that the downregulation of
IGF-I is causally related to the muscle wasting (Song et al, 2005). In
this study, we have shown IGF-I to attenuate completely protein
degradation induced by Ang II, as well as the increase in
expression and activity of the ubiquitin–proteasome proteolytic
pathway, suggesting that high circulatory levels of IGF-I may
be capable of suppressing the catabolic effect of Ang II. However,
it is known that malnourishment associated with cancer cachexia
lowers IGF-I levels (Pollak et al, 2004), suggesting that the
catabolic effect of Ang II may be maximal in the cachectic
state. The mechanism by which IGF-I attenuates the increase
in proteasome expression induced by Ang II has not been
evaluated, but IGF-I has been previously shown to suppress
increases in C-2, -3 and -8 proteasome subunit mRNAs in the
skeletal muscle of rats treated with dexamethasone as well as
mRNAs for ubiquitin and E2 (Chrysis et al, 2002). IGF-I has
been shown to suppress protein degradation in myotubes induced
by dexamethasone by suppressing expression of two muscle-
specific ubiquitin ligases (E3s), atrogin-1 and MURF1, which are
closely associated with muscle atrophy (Sacheck et al, 2004).
Certainly, the mechanism of induction of proteasome expression
by Ang II appears to be similar to that of PIF, since the effect of
both agonists is attenuated by EPA. Further studies will
concentrate on the mechanism of induction of proteasome
expression by Ang II.
In addition to the anticachectic effect, imidapril also produced a
stabilising effect on the growth of the MAC16 tumour, which
complicates the interpretation of the data on preserving body
weight, since weight loss in animals bearing the MAC16 tumour is
directly proportional to tumour mass (Beck and Tisdale, 1987).
Other agents, for example, EPA, which attenuate cachexia in the
MAC16 model, also have an inhibitory effect on tumour growth
(Beck et al, 1991), and this has been shown to be separate from the
anticachectic effect and due to starvation of the tumour of essential
fatty acids such as linoleic acid (Hudson et al, 1993). However, Ang
II is known to stimulate neovascularisation (Fernandez et al, 1985),
which in some cases is a requirement for tumour growth, while in
vitro it stimulates cell replication in the absence of blood vessels
(Paquet et al, 1990). ACE inhibitors retard growth of cancer cells
in vitro (Reddy et al, 1995) and inhibit tumour growth in vivo
(Hii et al, 1998), possibly through an effect on angiogenesis, while
long-term use of ACE inhibitors may protect against the
development of cancer (Lever et al, 1998). These results suggest
that imidapril may inhibit growth of the MAC16 tumour by a
mechanism unrelated to its effect on cachexia, and thus it is not
possible to determine unequivocally whether imidapril has a direct
anticachectic effect in this model.
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